Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRAF | P15056 | 3/20 | 0.81 |
| ▸ | KMT2A | Q03164 | 8/20 | 0.67 |
| ▸ | MEN1 | O00255 | 6/20 | 0.67 |
| ▸ | MITF | O75030 | 2/20 | 0.67 |
| ▸ | G6PD | P11413 | 2/20 | 0.65 |
| ▸ | GFER | P55789 | 1/20 | 0.65 |
| ▸ | GSK3A | P49840 | 1/20 | 0.65 |
| ▸ | GSK3B | P49841 | 1/20 | 0.65 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.62 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.62 |
| ▸ | PKM | P14618 | 1/20 | 0.62 |
| ▸ | POLB | P06746 | 4/20 | 0.61 |
| ▸ | METAP1 | P53582 | 1/20 | 0.59 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.59 |
| ▸ | MAPT | P10636 | 5/20 | 0.58 |
| ▸ | LMNA | P02545 | 3/20 | 0.58 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.58 |
| ▸ | MCL1 | Q07820 | 2/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.58 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5145120 | 0.83 | BRAF (0.68) | BRAFKMT2AMEN1MITFGSK3A | |
| SCHEMBL5145115 | 0.83 | BRAF (0.68) | BRAFKMT2AMEN1MITFGSK3A | |
| SCHEMBL3761898 | 0.81 | PIK3CG (0.67) | BRAFKMT2AMEN1MITFG6PD | |
| SCHEMBL5145111 | 0.81 | MAPT (0.68) | BRAFKMT2AMEN1MITFG6PD | |
| SCHEMBL6391067 | 0.81 | KMT2A (0.66) | BRAFKMT2AMEN1MITFGSK3A | |
| SCHEMBL10036665 | 0.81 | KMT2A (0.74) | BRAFKMT2AMEN1MITFG6PD | |
| SCHEMBL10018549 | 0.81 | KMT2A (0.74) | BRAFKMT2AMEN1MITFG6PD | |
| SCHEMBL6858664 | 0.79 | GSK3A (0.74) | BRAFKMT2AMEN1GSK3AGSK3B | |
| SCHEMBL3897840 | 0.78 | DUSP3 (0.73) | BRAFKMT2AMEN1GSK3AGSK3B | |
| SCHEMBL3897845 | 0.78 | DUSP3 (0.73) | BRAFKMT2AMEN1GSK3AGSK3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2010136804-A1 | PYRIMIDINE DERIVATIVES FOR USE AS ANTIBIOTICS | ASTON UNIVERSITY (GB) | 2010-12-02 | — | — | WO | disclosed |
| EP-1718308-A4 | METHODS OF MODULATING NEUROTROPHIN-MEDIATED ACTIVITY | PAINCEPTOR PHARMA CORP (CA) | 2007-07-18 | — | — | EP | disclosed |
| EP-1718308-A2 | METHODS OF MODULATING NEUROTROPHIN-MEDIATED ACTIVITY | PainCeptor Pharma Corp. (CA) | 2006-11-08 | — | — | EP | disclosed |
| US-20050282840-A1 | Methods of modulating neurotrophin-mediated activity | PAINCEPTOR PHARMA CORPORATION (CA) | 2005-12-22 | — | — | US | disclosed |
| WO-2005076695-A2 | METHODS OF MODULATING NEUROTROPHIN-MEDIATED ACTIVITY | PAINCEPTOR PHARMA CORPORATION (CA) | 2005-08-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050282840-A1 | Methods of modulating neurotrophin-mediated activity | NGF, BDNF, NTRK2 | BRAF 4079/4885KMT2A 4410/4885MEN1 4004/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.